ORIC Pharmaceuticals (FRA:4TZ) ROE % Adjusted to Book Value: -11.46% (As of Mar. 2026)


FRA:4TZ ORIC Pharmaceuticals Inc FRA:4TZ
32 GF Score
Price €9.13
! 3 Warning Signs
View Full Analysis

What is ORIC Pharmaceuticals ROE % Adjusted to Book Value?

ORIC Pharmaceuticals FRA:4TZ -2.77% 32 ROE % Adjusted to Book Value is -11.46% as of Mar. 2026. GuruFocus rates FRA:4TZ with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

ORIC Pharmaceuticals's ROE % for the quarter that ended in Mar. 2026 was -35.99%. ORIC Pharmaceuticals's PB Ratio for the quarter that ended in Mar. 2026 was 3.14. ORIC Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -11.46%.

ORIC Pharmaceuticals ROE % Adjusted to Book Value Related Terms

ORIC Pharmaceuticals ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for ORIC Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ORIC Pharmaceuticals ROE % Adjusted to Book Value Chart

ORIC Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial -13.38 -34.51 -20.30 -23.34 -19.06

ORIC Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -28.34 -19.51 -12.87 -14.92 -11.46

FRA:4TZ vs DRTS, OLMA, KURA: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, ORIC Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ORIC Pharmaceuticals ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ORIC Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where ORIC Pharmaceuticals's ROE % Adjusted to Book Value falls into.


FRA:4TZ
32GF Score
ORIC Pharmaceuticals Inc FRA:4TZ
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ORIC Pharmaceuticals ROE % Adjusted to Book Value Calculation

ORIC Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-39.46% / 2.07
=-19.06%

ORIC Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-35.99% / 3.14
=-11.46%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -11.46% mean?
ORIC Pharmaceuticals (FRA:4TZ) has a ROE % Adjusted to Book Value of -11.46% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on ORIC Pharmaceuticals and its competitors.
Is ORIC Pharmaceuticals' ROE % Adjusted to Book Value too high?
ORIC Pharmaceuticals' current ROE % Adjusted to Book Value is -11.46%. Overall, ORIC Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does ORIC Pharmaceuticals' ROE % Adjusted to Book Value compare to DRTS and OLMA?
ORIC Pharmaceuticals' ROE % Adjusted to Book Value of -11.46% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on ORIC Pharmaceuticals and its competitors. ORIC Pharmaceuticals's current ROE % Adjusted to Book Value is -11.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ORIC Pharmaceuticals stock overvalued right now?
ORIC Pharmaceuticals (FRA:4TZ) has a current ROE % Adjusted to Book Value of -11.46%. The current ROE % Adjusted to Book Value is -11.46%. ORIC Pharmaceuticals' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For ORIC Pharmaceuticals (FRA:4TZ), the current ROE % Adjusted to Book Value is -11.46% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ORIC Pharmaceuticals Business Description

Other Exchanges ORIC:USA
Address 240 E. Grand Avenue, 2nd Floor, South San Francisco, CA, USA, 94080
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
32GF Score

Get the complete analysis for FRA:4TZ

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.13
Price